On July 24, BEIGENE rose 4.13% in regular trading, trading at 201.0 HKD/share, with turnover of approximately HKD 165 million. The stock was lifted by multiple positive catalysts announced in recent days.

On the news front, the company announced on July 23 an additional $300 million investment to expand its US production footprint, further strengthening global commercialization capacity. Simultaneously, Amgen and BEIGENE jointly registered DeLLphi-315, the first Phase 3 clinical trial evaluating a subcutaneous formulation of Tarlatamab for recurrent extensive-stage small cell lung cancer, marking a significant pipeline advancement.

Additionally, the company's core product Brukinsa recently achieved the primary endpoint in the MANGROVE Phase 3 trial for first-line mantle cell lymphoma treatment, demonstrating a 43% reduction in disease progression or death risk versus standard immunochemotherapy. The company plans to pursue global regulatory submissions in the second half of the year. BEIGENE is scheduled to hold its Q2 earnings call on August 5.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)